GET THE APP

Hemodialysis Impact Factor | Open Access Journals
Journal of Nephrology & Therapeutics

Journal of Nephrology & Therapeutics

ISSN: 2161-0959

Open Access

Hemodialysis Impact Factor

In terms of annual research, the United States, India, Japan, Brazil and Canada are among the main countries where a maximum of studies related to industry management are carried out. As reported in Effects of azilsartan in ambulatory patients on maintenance hemodialysis: night and home monitoring, special edition. Hemodialysis is a procedure to remove metabolic waste or toxic substances from the bloodstream by dialysis. Hypertension is widespread and closely associated with cardiovascular disease (CVD) in patients treated with hemodialysis (HD). A recent meta-analysis and two observational studies, including the Japanese Kidney Data Registry and the U.S. Kidney Data System, have shown better results in patients treated with antihypertensive agents than in those treated with antihypertensive agents in HD patients. Among antihypertensive drugs, the inhibitory role of the reninangiotensin system and remains debatable. Recently, an in vitro study showed that azilsartan, a newly developed angiotensin receptor antagonist (ARB), has higher affinity and slower dissociation of the angiotensin type 1 receptor than other ARB . In addition, recent clinical studies have clearly demonstrated that once daily administration of azilsartan consistently lowers blood pressure over 24 hours and improves nocturnal hypertension more effectively than other ARBs.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Medical Sciences

Google Scholar citation report
Citations: 784

Journal of Nephrology & Therapeutics received 784 citations as per Google Scholar report

Journal of Nephrology & Therapeutics peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward